Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates
Regeneron’s closely-watched bispecific continues to ring up high response rates
Regeneron’s high-profile bispecific REGN1979 is back in the spotlight at the European Hematology Association scientific confab. And while the stellar numbers we saw at ASH have eroded somewhat as more blood cancer patients are evaluated, the response rates for this CD3/CD20 drug remain high.
A total of 13 out of 14 follicular lymphomas responded to the drug, a 93% ORR, down from 100% at the last readout. In 10 out of 14, there was a complete response. In diffuse large B-cell lymphoma the response rate was 57% among patients treated at the 80 mg to 160 mg dose range. They were all complete responses. And 2 of these Cars were for patients who had failed CAR-T therapy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters